Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Inhale will provide expertise and exclusive manufacturing for the reagent used in the PEGylation of Infergen, while InterMune will be responsible for…
It's been a decade since Roche bought InterMune for $8.3 billion on the promise of its idiopathic pulmonary fibrosis (IPF) therapy Esbriet; Esbriet was able to…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
In October 2002, InterMune Inc. and Inhale Therapeutic Systems Inc. entered a collaboration to develop a PEGylated formulation of Infergen (interferon alfacon-1), branded PEG-Infergen, for the treatment of chronic hepatitis C. Inhale contributed its PEGylation technology and exclusive manufacturing of the PEGylation reagent, while InterMune was responsible for preclinical and clinical development and North American commercialization. Inhale was eligible for milestone payments as the program advanced through the clinic plus royalties on product sales; specific financial terms were not disclosed.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| InterMune Inc. / Inhale Therapeutic Systems Inc. (this deal) | 2002 | — | — |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
| Novartis AG / Hexal AG | 2002 | $8.3B | 75 |
← Browse all deals · How we score deals
More: 2002 deals